Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and non-invasive measures of enthesitis

Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and non-invasive measures of enthesitis

Brief description of study

The purpose of this study is to determine how psoriatic nail disease is affected by secukinumab. Secukinumab (Cosentyx®) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis in adults. While secukinumab has already been approved to treat psoriasis, the goal of this study is to look more closely at how it affects specific measures of psoriatic nail disease including imaging and patient reported measurements. Secukinumab is known as a biologic, and works by blocking the activity of a specific protein in the immune system, interleukin-17A, which is believed to be involved in psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Secukinumab will be given at the currently approved dose for psoriasis which is 300 mg subcutaneously (under the skin) every 4 weeks with a loading regimen of 300 mg at a first baseline visit and then at Weeks 1, 2, 3, and 4.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nail Psoriasis
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 09 Mar 2024. Study ID: 834149

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center